L2 Bioscience

L2 Bioscience is a clinical-stage biotechnology company dedicated to the discovery and development of novel immuno-oncology therapies targeting the LILRB family of receptors. The company's primary focus is on modulating myeloid-derived immune suppression within the tumor microenvironment to enhance anti-tumor immune responses. Its lead candidate, L2B-001, is a humanized monoclonal antibody targeting LILRB2 currently undergoing Phase 1 clinical evaluation for advanced solid tumors. L2 Bioscience utilizes a cross-border R&D strategy with operations in both the United States and China to accelerate the delivery of innovative treatments to cancer patients globally. The company was founded based on pioneering research into the LILRB receptor family and its role in immune evasion and cancer progression.